Key Metrics of GRAIL Inc.
Revenue$93.1M▲ 67.6% YoYFY 2023
Operating income−$1.5B▲ 72.2% YoY
Net profit−$1.5B▲ 72.9% YoY
Shareholders' equity—
Market cap$5.7BGRAL · $127.06
Competitors10identified
About GRAIL Inc.
Sectors
Company details
- Listed
- Nasdaq: GRAL
Operational Areas of GRAIL Inc.
Pharmaceuticals & Healthcare›Formulations & Contract Manufacturing
Company summary
Legal nameGRAIL Inc.
TickerGRAL
ExchangeNasdaq
CountryUnited States
SEC CIK0001699031
Listed since—
IndustryMedical Specialities
SectorPharmaceuticals & Healthcare · Formulations & Contract Manufacturing
Website—
US market & SEC filings
GRAL · Nasdaq · SEC CIK 0001699031
Last price · 23 Oct 2026
$127.06
−4.18%
Market cap$5.7B
P/E—On FY 2023 diluted EPS
Volume653,264
SectorHealth CareMedical Specialities
Country · IPOUnited States
GRAL share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of GRAIL Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | lilly.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | jjmt.com.tw | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pg.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | merck.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | amgen.com | 1983 | United States | |
| Part of Gilead Sciences. | gilead.com | 1992 | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | abbott.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pfizer.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | bms.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | marriott.com.cn | — | United States |
Similar companies
S
Sai Life Sciences LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
B
Brooks Laboratories LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
M
Morepen Laboratories LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
N
Nectar Lifesciences LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
T
Themis Medicare LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
S
Sakar Healthcare LimitedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
I
IOL Chemicals and Pharmaceuticals Ltd. (India)Pharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
P
Poly Medicure (India)Pharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.